Given the variable role that NF-κB plays in HPV+ OPSCC tumorigenesis, we hypothesized that tumor groups based on NF-κB related gene expression may correlate with treatment outcome, considering that tumors lacking defects in TRAF3 and CYLD may have unrecognized mechanisms driving constitutive NF-κB activation. This evidence concerns the gene CYLD and neoplasm.